Sugi Predict

Sugi Predict / Compounds / SCHEMBL1151183

SCHEMBL1151183

SCHEMBL1151183

N#Cc1cccc(-c2ccc(=O)[nH]n2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.57
▸ XDH P47989 1/20 0.56
▸ IDO1 P14902 2/20 0.55
▸ MAP4K4 O95819 1/20 0.48
▸ GSK3A P49840 1/20 0.48
▸ PGR P06401 4/20 0.48
▸ MAOB P27338 2/20 0.48
▸ PDE4A P27815 1/20 0.47
▸ PDE4B Q07343 1/20 0.47
▸ PDE4C Q08493 1/20 0.47
▸ PDE4D Q08499 1/20 0.47
▸ CLK4 Q9HAZ1 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ USP30 Q70CQ3 1/20 0.46
▸ GRK6 P43250 1/20 0.45
▸ GPR119 Q8TDV5 1/20 0.45
▸ PDE3B Q13370 1/20 0.44
▸ PDE3A Q14432 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29550259 1.00 CYP1A2 (0.57) CYP1A2XDHIDO1MAP4K4GSK3A
Hydrochloric Acid SCHEMBL1296821 0.98 CYP1A2 (0.56) CYP1A2XDHIDO1MAP4K4GSK3A
SCHEMBL13994269 0.84 CYP1A2 (0.57) CYP1A2XDHIDO1PDE4APDE4B
SCHEMBL10353459 0.83 CYP1A2 (0.74) CYP1A2PDE4APDE4BPDE4CPDE4D
SCHEMBL1151830 0.80 LMNA (0.61) CYP1A2MAOBPDE4APDE4BPDE4C
SCHEMBL15113272 0.79 PGR (0.49) CYP1A2PGRPDE4APDE4BPDE4C
SCHEMBL24156317 0.78 HPGDS (0.46) CYP1A2XDHIDO1PDE4APDE4B
SCHEMBL7298232 0.77 CYP1A2 (0.65) CYP1A2PDE4APDE4BPDE4CPDE4D
SCHEMBL30250881 0.76 IDO1 (0.56) XDHIDO1MAP4K4PGRMAOB
SCHEMBL5269506 0.76 L3MBTL1 (0.59) XDHIDO1MAP4K4GSK3APGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114736191-B Terpetinib intermediate and preparation method and application thereof 上海工程技术大学 2023-08-08 — — CN claimed
CN-115583939-A Synthesis method of Tepontinib intermediate 苏州莱安医药化学技术有限公司 2023-01-10 — — CN claimed
CN-114736191-A Tepritinib intermediate and preparation method and application thereof 上海工程技术大学 2022-07-12 — — CN claimed
US-20210139464-A1 PYRIMIDINE DERIVATIVE CONTAINING ONE DEUTERIUM ATOM AND PREPARATION PROCESS AND USE THEREOF Guangdong CS-Lewwin Drug Research Co., Ltd. (CN) 2021-05-13 — — US claimed
CN-111747930-A Pyrimidine derivative containing deuterium atom and preparation method and application thereof 广东莱恩医药研究院有限公司 2020-10-09 — — CN claimed
EP-4599885-A2 COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA Merck Patent GmbH (DE) 2025-08-13 — — EP disclosed
CN-119684263-A Synthetic method of terpetinib and key intermediate thereof 苏州莱安医药化学技术有限公司 2025-03-25 — — CN disclosed
US-12258331-B2 Pyrimidine derivative and preparation process and use thereof GUANGDONG LEWWIN PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) 2025-03-25 — — US disclosed
US-12202820-B2 Pyrimidine derivative and preparation process and use thereof GUANGDONG LEWWIN PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) 2025-01-21 — — US disclosed
US-12168654-B2 Pyrimidine derivative containing one deuterium atom and preparation process and use thereof GUANGDONG LEWWIN PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) 2024-12-17 — — US disclosed
US-20240277711-A1 COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA MERCK PATENT GMBH (DE) 2024-08-22 — — US disclosed
CN-118084871-B Compound for targeted degradation of c-Met protein and preparation method and application thereof 中国药科大学 2024-07-09 — — CN disclosed
EP-2164843-A1 PYRIDAZINONE DERIVATES Merck Patent GmbH (DE) 2010-03-24 — — EP disclosed
EP-2164844-A1 PYRIMIDINYL PYRIDAZINONE DERIVATES Merck Patent GmbH (DE) 2010-03-24 — — EP disclosed
WO-2009129905-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2009-10-29 — — WO disclosed
WO-2009129905-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2009-10-29 — — WO disclosed
WO-2009006959-A1 PYRIDAZINONE DERIVATES MERCK PATENT GMBH (DE) 2009-01-15 — — WO disclosed
WO-2009006959-A1 PYRIDAZINONE DERIVATES MERCK PATENT GMBH (DE) 2009-01-15 — — WO disclosed
WO-2009007074-A1 PYRIMIDINYL PYRIDAZINONE DERIVATES MERCK PATENT GMBH (DE) 2009-01-15 — — WO disclosed
US-4092311-A Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates AMERICAN CYANAMID COMPANY (US) 1978-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139464-A1 PYRIMIDINE DERIVATIVE CONTAINING ONE DEUTERIUM ATOM AND PREPARATION PROCESS AND USE THEREOF DUT, TYMP, DCTD CYP1A2 3180/4885XDH 1303/4885IDO1 1597/4885
US-12202820-B2 Pyrimidine derivative and preparation process and use thereof MET, HCCS, MTR CYP1A2 1717/4885XDH 608/4885IDO1 721/4885
US-20240277711-A1 COMPOUNDS FOR THE TREATMENT OF GLIOBLASTOMA MET, MGMT, EGFR CYP1A2 4281/4885XDH 4400/4885IDO1 3580/4885
US-12258331-B2 Pyrimidine derivative and preparation process and use thereof MTR, HCCS, MET CYP1A2 2437/4885XDH 642/4885IDO1 610/4885
US-12168654-B2 Pyrimidine derivative containing one deuterium atom and preparation process and use thereof DUT, TYMP, DCTD CYP1A2 3180/4885XDH 1303/4885IDO1 1597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.